Compass therapeutics reports 2025 first quarter financial results and provides corporate update

Tovecimig (dll4 x vegf-a bispecific antibody) met the primary endpoint in the ongoing randomized phase 2/3 study in patients with biliary tract cancer (btc). achieved a 17.1% overall response rate (orr), including one complete response, compared to a 5.3% orr for paclitaxel alone, in patients with btc treated in the second-line setting.
CMPX Ratings Summary
CMPX Quant Ranking